AstraZeneca has terminated a partnership with Pieris Pharmaceuticals on respiratory drug candidate elarekibep, forcing the latter to slash staff and look into its “strategic options”. AZ ...

Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise.In order ...

Pieris’ lead candidate, elarekibep, is an inhaled IL-4 receptor alpha inhibitor under development for the treatment of asthma. The non-clinical study was conducted over a period of 13 weeks on ...

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology ...

Pieris holds the option to co-develop and retain U.S. commercial rights for up to three programs beyond PRS-332, with Servier overseeing worldwide development and commercialization of the four ...

Pieris Pharmaceuticals has filed to step up to Nasdaq from OTCQB and add $35 million (€31 million) to its bank balance in the process. The listing would end Pieris' short stay on OTCQB, which ...

Pieris Pharmaceuticals Inc., a small biotech behind a suite of inhalable, engineered proteins it calls anticalins, saw its stock surge more than 100% after signing a major research-and-development ...

AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals. The agreement sets Pieris up to move respiratory candidate PRS-060 into the ...

Pieris Pharmaceuticals is a good speculative biotech to look into. I highlighted a few of the drugs in the pipeline, which were PRS-060 for asthma and PRS-343 for HER2 gastric cancer.